A study profiled proteomes of plasma-derived exosomes from patients with metastatic colorectal cancer (mCRC) to identify candidate biomarkers for disease state and therapeutic response. The analysis detected protein signatures linked to metastatic burden and immune modulation, offering potential noninvasive biomarkers for stratification and monitoring. Researchers propose exosome proteomics as a complementary liquid‑biopsy approach to genomics, emphasizing that protein cargo can reflect tumor phenotype and microenvironment interactions. The study calls for larger cohorts and orthogonal validation but positions exosome profiling as a promising tool for mCRC clinical management.